As things appear at the moment, Sanofi hasn't achieved its ambitions with drug rilzabrutinib that management had otherwise hoped when the French pharmaceutical company acquired the compound via its acquisition of Prinicipia Biopharma in 2020.
In any case, rilzabrutinib has showed itself to be a real fiasco within the field of dermatology. Here, the medication failed to pass its phase III trial as a treatment for two variants of the rare autoimmune skin disease pemfigus vulgaris and pemfigus foliaceus. The condition is characterized by blisters on skin and mucus membranes, sometimes leading to death among patients with compromised immune systems.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.